Cagrilintide
- Home
- Cagrilintide
Cagrilintide
Cagrilintide is a long-acting amylin analogue being investigated for its potential role in weight management and metabolic health. It is designed to mimic certain effects of the naturally occurring hormone amylin, which is involved in appetite regulation, satiety and other metabolic processes.
Cagrilintide is currently being evaluated in Phase 3 clinical development for obesity and overweight-related conditions. Research has focused on its ability to influence appetite and food intake, with clinical studies investigating its potential to support meaningful reductions in body weight.
Key Research Features
- Long-acting amylin analogue
- Investigated for once-weekly administration
- Studied for weight-management applications
- Designed to influence appetite and feelings of fullness
- Currently undergoing Phase 3 clinical development
- Being studied both as a standalone treatment and in combination with semaglutide
Research Overview
Clinical research has demonstrated meaningful weight reduction with cagrilintide in adults with overweight or obesity. In a Phase 3 analysis, once-weekly cagrilintide 2.4 mg produced an average body-weight reduction of approximately 11.8% after 68 weeks compared with 2.3% with placebo. Gastrointestinal effects were among the commonly reported adverse events in the study.
Cagrilintide is also being studied as part of CagriSema, an investigational combination of cagrilintide and semaglutide. The combination is designed to target complementary pathways involved in appetite, satiety and metabolic regulation.
Important Notice
Cagrilintide is an investigational compound and is not currently an approved medicine for routine clinical use. This product description is provided for informational and research purposes only and should not be interpreted as medical advice, a treatment recommendation, or a claim that the product is approved for human use.
Use, handling, storage and administration of any investigational compound should be determined by qualified professionals and applicable regulatory requirements.
